You have no items in your shopping cart.
Product Details
| Alternate Name | CP-358774, OSI-774 |
|---|---|
| Appearance | White to off-white solid |
| CAS # | 183319-69-9 |
| Molecular Formula | C₂₂H₂₃N₃O₄.HCl |
| Molecular Weight | 429.9 |
| Purity | ≥99% by HPLC |
| Solubility | DMSO |
| SMILES | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl |
| InChi | InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H |
| InChi Key | GTTBEUCJPZQMDZ-UHFFFAOYSA-N |
| PubChem CID | 176871 |
| MDL Number | MFCD07781272 |
| Handling | Protect from light and moisture |
| Storage Conditions | -20°C |
| Shipping Conditions | RT |
| USAGE | For Research Use Only! Not For Use in Humans. |
Details
Erlotinib is an inhibitor of human Epidermal growth factor receptor (EGFR) tyrosine kinase (IC₅₀ = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC₅₀ = 20 nM). Studies in cell lines and enzyme assays have both shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl.
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
Cheng et al., The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion. Mol. Cancer Res., Mar 2015; 13: 575 - 583.
Dayekh et al., Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors. Mol. Cancer Ther., Nov 2014; 13: 2559 - 2571.
For more citations of this product click here
